Inhibition of angiogenesis by interleukin 4

Journal of Experimental Medicine

Volumn 188, Issue 6, 1998, Pages 1039-1046

  Volpert, Olga V ^a   Fong, Tim ^a   Koch, Alisa E ^a   Peterson, Jeffrey D ^a   Waltenbaugh, Carl ^a   Tepper, Robert I ^b   Bouck, Noël P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Cornea assay; Endothelial cell; Migration; Neovascularization; Tumor angiogenesis

Indexed keywords

INTERLEUKIN 4;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CORNEA NEOVASCULARIZATION; GROWTH INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR BLOOD FLOW;

ADENOCARCINOMA; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; CORNEA; CULTURE MEDIA, CONDITIONED; CULTURE MEDIA, SERUM-FREE; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-4; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; TUMOR CELLS, CULTURED;

EID: 0032555937     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.6.1039     Document Type: Article

References (53)

1. Paul, W.E. 1991. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 77:1859-1870.
2. Kopf, M., G. Le Gros, M. Bachmann, K.C. Lamers, H. Bluethmann, and G. Kohler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 362:245-248.
3. Kuhn, R., K. Rajewsky, and W. Muller. 1991. Generation and analysis of interleukin-4 deficient mice. Science. 254: 707-710.
4. Ohara, J., and W.E. Paul. 1987. Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature. 325:537-540.
5. Mosmann, T.R., T. Yokota, R. Kastelein, S.M. Zurawski, N. Arai, and Y. Takebe. 1987. Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL-4): comparison of normal and recombinant, mouse and human IL-2 and BSF-1 (IL-4). J. Immunology. 138:1813-1816.
6. Sugamura, K., H. Asao, M. Kondo, N. Tanaka, N. Ishii, K. Ohbo, M. Nakamura, and T. Takeshita. 1996. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu. Rev. Immunol. 14:179-205.
7. Puri, R.K., and J.P. Siegel. 1993. Interleukin-4 and cancer therapy. Cancer Investig. 11:473-486.
8. Toi, M., R. Bicknell, and A.L. Harris. 1992. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 52:275-279.
9. Obiri, N.I., G.G. Hillman, G.P. Haas, S. Sud, and R.K. Puri. 1993. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in-vitro by interleukin-4. J. Clin. Invest. 91:88-93.
10. Topp, M.S., C.A. Papadimitriou, F. Eitelbach, M. Koenigsmann, E. Oelmann, B. Koehler, D. Oderberg, B. Reufi, H. Stein, E. Thiel, and W.E. Berdel. 1995. Recombinant human interleukin 4 has antiproliterative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res. 55:2173-2176.
11. Tepper, R.I., R.L. Coffman, and P. Leder. 1992. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science. 257:548-551.
12. Tepper, R.I. 1994. The eosinophil-mediated antitumor activity of intorleukin-4. J. Allergy Clin. Immunol. 94:1225-1231.
13. Schwarz, M.A., L. Tardelli, H.D. Macosko, L.M. Sullivan, S.K. Narula, and J.S. Fine. 1995. Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res. 55:3692-3696.
14. Hillman, G.G., E. Younes, D. Visscher, E. Ali, J.S. Lam, E. Montecillo, J.E. Pontes, G.P. Haas, and R.K. Puri. 1995. Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model. Cell. Immunol. 160:257-263.
15. Folkman, J. 1995. Tumor Angiogenesis. In The Molecular Basis of Cancer. J. Mendelsohn, P.M. Howley, M.A. Israel, and L.A. Liotta, editors. W.B. Saunders Company, Philadelphia, PA. 206-232.
16. Prehn, R.T. 1993. Two competing influences that may explain concomitant tumor resistance. Cancer Res. 53:3266-3269.
17. Ohira, T., Y. Ohe, Y. Heike, E.R. Podack, K.J. Olsen, K. Nishio, M. Nishio, Y. Miyahara, Y. Funayama, H. Ogasawara, et al. 1994. In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant. J. Cancer Res. Clin. Oncol. 120:631-635.
18. O'Reilly, M.S., L. Holmgren, Y. Shing, C. Chen, R.A. Rosenthal, M. Moses, W.S. Lane, Y. Cao, E.H. Sage, and J. Folkman. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79: 315-328.
19. O'Reilly, M., T. Boehm, Y. Shing, N. Fukai, G. Vasios, W.S. Lane, E. Flynn, J.R. Birkhead, B.R. Olsen, and J. Folkman. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277-285.
20. Volpert, O.V., J. Lawler, and N.P. Bouck. 1998. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc. Natl. Acad. Sci. USA. 95:6343-6348.
21. Saleh, M., I.D. Davis, and A.F. Wilks. 1997. The paracrine role of tumor-derived mIL-4 on tumor-associated endothelium. Int. J. Cancer. 72:664-672.
22. Schnyder, B., S. Lugli, N. Feng, H. Etter, R.A. Lutz, B. Ryffel, K. Sugamura, H. Wunderli-Allenspach, and R. Moser. 1996. Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common γ chain. Blood. 87:4286-4295.
23. Palmer-Crocker, R.L., C.C.W. Hughes, and J.S. Pober. 1996. IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the γc chain. J. Clin. Invest. 98:604-609.
24. Kotowicz, K., R.E. Callard, K. Friederich, D.J. Matthews, and N. Klein. 1996. Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor. Int. Immunol. 8:1915-1925.
25. Swerlick, R.A., K.H. Lee, L.-J. Li, N.T. Sepp, S.W. Caughman, and T.J. Lawley. 1992. Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J. Immunol. 149:698-705.
26. Haraldsen, G., D. Kvale, B. Lein, I.N. Farstad, and P. Brandtzaeg. 1996. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human intestinal microvascular endothelial cells. J. Immunol. 156:2558-2565.
27. Petzelbauer, P., J.R. Bender, J. Wilson, J.S. Pober. 1993. Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture. J. Immunol. 151:5062-5072.
28. Bergese, S.D., E.H. Huang, R.P. Pelletier, M.B. Widmer, R.M. Ferguson, and C.G. Orosz. 1995. Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-α or IL-4 and is not required for allograft rejection. Am. J. Pathol. 147:166-175.
29. Toi, M., A.L. Harris, and R. Bicknell. 1991. Interleukin-4 is a potent mitogen for capillary endothelium. Biochem. Biophys. Res. Commun. 174:1287-1293.
30. Ohara, J., and W.E. Paul. 1985. Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature. 315:333-336.
31. Leder, A., P.K. Pattengale, A. Kuo, T.A. Stewart, and P. Leder. 1986. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell. 45:485-495.
32. Tepper, R.I., P.K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 57:503-512.
33. Dameron, K.M., O.V. Volpert, M.A. Tainsky, and N. Bouck. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265:1582-1584.
34. Polverini, P.J., N.P. Bouck, and F. Rastinejad. 1991. Assay and purification of a naturally occurring inhibitor of angiogenesis. Methods Enzymol. 198:440-450.
35. Kenyon, B.M., E.E. Voest, C.C. Chen, E. Flynn, J. Folkman, and R.J. D'Amato. 1996. A model of angiogenesis in the mouse cornea. Investig. Ophthalmol. Vis. Sci. 37:1625-1632.
36. Finkelman, F.D., I.M. Katona, J.F. Urban, C.M. Snapper, J. Ohara, and W.E. Paul. 1986. Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc. Natl. Acad. Sci. USA. 83:9675-9678.
37. Aman, M.J., N. Tayebi, N.I. Obir, R.K. Puri, W.S. Modi, and W.J. Leonard. 1996. cDNA cloning and characterization of the human interleukin 13 receptor α chain. J. Biol. Chem. 271:29265-29270.
38. Lugli, S.M., N. Feng, M.H. Heim, M. Adam, B. Schnyder, H. Etter, M. Yamage, H-P. Eugster, R.A. Lutz, G. Zurawski, and R. Moser. 1997. Tumor necrosis factor α enhances the expression of the interleukin (IL)-4 receptor α-chain on endothelial cells increasing IL-4 or IL-13-induced Stat6 activation. J. Biol. Chem. 272:5487-5494.
39. Orchansky, P.L., S.D. Ayres, D.J. Hilton, and J.W. Schrader. 1997. An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits responses to IL-4. J. Biol. Chem. 272:22940-22947.
40. Tolsma, S.S., O.V. Volpert, D.J. Good, W.A. Frazier, P.J. Polverini, and N. Bouck. 1993. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 122:497-511.
41. Gately, S., P. Twardowski, M.S. Stack, M. Patrick, L. Boggio, D.L. Cundiff, H.W. Schnaper, L. Madison, O. Volpert, N. Bouck, et al. 1996. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56:4887-4890.
42. Wu, Z., M.S. O'Reilly, J. Folkman, and Y. Shing. 1997. Suppression of tumor growth with recombinant murine angiostatin. Biochem. Biophys. Res. Commun. 236:651-654.
43. Sim, B.K.L., M.S. O'Reilly, H. Liang, A.H. Fortier, W. He, J.W. Madsen, R. Lapcevich, and C.A. Nacy. 1997. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57:1329-1334.
44. Boehm, T., J. Folkman, T. Browder, and M.S. O'Reilly. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:404-407.
45. Golumbek, P.T., A.J. Lazenby, H.I. Levitsky, L.M. Jaffee, H. Karasuyama, M. Baker, and D.M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 254:713-716.
46. Allen, J.B., H.L. Wong, G.L. Costa, M.J. Bienkowski, and S.M. Wahl. 1993. Suppression of monocyte function and differential regulation of IL-1 and IL-1rα by IL-4 contribute to resolution of experimental arthritis. J. Immunol. 151:4344-4351.
47. van-Roon, J.A., J.L. van-Roy, F.H. Gmelig-Meyling, F.P. Lafeber, and J.W. Bijlsma. 1996. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum. 39:829-835.
48. Hurford, R.K., Jr., G. Dranoff, R.C. Mulligan, and R.I. Tepper. 1995. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nature Genet. 10:430-435.
49. Bouck, N., V. Stellmach, and S. Hsu. 1996. How tumors become angiogenic. Adv. Cancer Res. 69:135-174.
50. Dawson, D.W., S.F.A. Pearce, R. Zhong, R.L. Silverstein, W.A. Frazier, and N.P. Bouck. 1997. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138:707-717.
51. Dawson, D.W., and N. Bouck. 1998. Thrombospondin as an inhibitor of angiogenesis. In Antiangiogenic Agents in Cancer. B.A. Teicher, editor. Humana Press, Totowa, NJ. In press.
52. Teicher, B.A., Y. Emi, Y. Kakeji, and D. Northey. 1996. TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Eur. J. Cancer. 32A:2461-2466.
53. Good, D.J., P.J. Polverini, F. Rastinejad, M.M. Le Beau, R.S. Lemons, W.A. Frazier, and N.P. Bouck. 1990. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA. 87:6624-6628.